Overview
Cerus Q3 total revenue up 19% yr/yr, driven by 15% product revenue growth
Adjusted EBITDA for Q3 beats analyst expectations
Company raises full-year 2025 product revenue guidance to $202 mln - $204 mln
Outlook
Cerus raises full-year 2025 product revenue guidance to $202 mln - $204 mln, from prior outlook of $200 mln-$203 mln
Company expects full-year 2025 IFC revenue between $16 mln and $17 mln
Result Drivers
IFC DEMAND - Increased U.S. hospital demand for INTERCEPT Fibrinogen Complex, supported by positive case studies from academic hospitals
GLOBAL EXECUTION - Strong global commercial execution and growing awareness of INTERCEPT Blood System benefits drove product revenue growth
GOVERNMENT CONTRACTS - Revenue increase from government contracts due to Phase 3 RedeS trial and pathogen reduction technology development
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Income | -$20,000 | ||
Q3 Adjusted EBITDA | Beat | $5 mln | $2.87 mln (3 Analysts) |
Q3 Gross Margin | 53.40% | ||
Q3 Gross Profit | $28.10 mln | ||
Q3 Operating Expenses | $34.40 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Cerus Corp is $5.00, about 71% above its November 5 closing price of $1.45
Press Release: ID:nBwbYqdz2a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)